Do All Stage IA Pancreatic Cancer Patients Need Adjuvant Chemotherapy?

John M Lyons, Mei-Chin Hsieh, Kenneth C Avanzino, Mohammad Al Efishat, Quyen Chu

Abstract read

In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John M LyonsDepartment of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0003-0340-1312

Mei-Chin HsiehProgram of Epidemiology and Population Health, School of Public Health, LSUHSC, New Orleans, LA 70112, USA.ORCID 0000-0001-7842-1225

Kenneth C AvanzinoDepartment of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.

Mohammad Al EfishatDepartment of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0000-0002-2174-5007

Quyen ChuDepartment of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.ORCID 0009-0002-4837-5218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNational guidelines recommend adjuvant chemotherapy (AC) following resection for all stages of pancreatic cancer (PDAC), but the benefit of AC in Stage IA disease remains unclear. The objective of this study was to identify a subgroup of patients with Stage IA PDAC that could possibly forego AC. STUDY

designThe National Cancer Database (NCDB) was queried to identify all patients with Stage IA PDAC diagnosed from 2010 to 2021. Patients who received AC were compared to those who did not. Multivariable analysis was conducted to identify risk factors associated with overall survival (OS).

resultsThere were 1421 patients eligible for analysis. On multivariable analysis, we found nine factors associated with worse overall OS: advanced age (

conclusionsAC does not appear to benefit Stage IA PDAC patients with fewer than three risk factors indicating that it may be safe to omit AC in these individuals.

Indexed as

adjuvant therapychemotherapypancreas cancerstage IA

Identifiers

PMID42073522

DOI10.3390/cancers18081195

PMCPMC13115334

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.